# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Familial non-Hodgkin lymphoma

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 391 results.
Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma
Status: Recruiting
Last Changed: Oct 26, 2017
First Received: Sep 11, 2013
Disease(s): Non-Hodgkin Lymphoma
Intervention(s): Lenalidomide/Rituximab
Locations: Institut Paoli-Calmettes, Marseille, France
Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)
Status: Recruiting
Last Changed: Mar 11, 2020
First Received: Oct 18, 2018
Disease(s): Non Hodgkin Lymphoma
Intervention(s): Tenalisib,
Locations: Clearview Cancer Institute, Huntsville, Alabama, United States
Colorado Blood Cancer Institute, Denver, Colorado, United States
Florida cancer specialists & Research Institute, Florida City, Florida, United States
Florida Cancer Specialist/ South, Fort Myers, Florida, United States
Florida Cancer Specialists/North, Saint Petersburg, Florida, United States
... and 8 other locations.
Treatment of Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy
Status: Recruiting
Last Changed: Mar 13, 2020
First Received: Jan 02, 2019
Disease(s): Non-Hodgkin Lymphoma
Intervention(s): CD19-TriCAR-T/SILK
Locations: Hainan Cancer Hospital, Haikou, Hainan, China
Hainan General Hospital, Haikou, Hainan, China
The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China
Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
Status: Recruiting
Last Changed: Sep 27, 2019
First Received: Oct 16, 2018
Disease(s): Solid Tumors, Non-Hodgkin Lymphoma
Intervention(s): ADG106
Locations: Horizon Oncology Research, Lafayette, Indiana, United States
NEXT Oncology, San Antonio, Texas, United States
Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)
Status: Not yet recruiting
Last Changed: Jan 28, 2020
First Received: Jan 27, 2020
Disease(s): Non Hodgkin Lymphoma
Intervention(s): UCD19 CAR T Cells
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients
Status: Recruiting
Last Changed: Feb 07, 2020
First Received: Aug 01, 2018
Disease(s): Non-Hodgkin Lymphoma
Intervention(s): Tisagenlecleucel
Locations: Childrens Hospital Los Angeles, Los Angeles, California, United States
UCSF Medical Center, San Francisco, California, United States
Children s National Health System, Washington, District of Columbia, United States
Childrens Healthcare of Atlanta At Scottish Rite, Atlanta, Georgia, United States
Johns Hopkins Oncology Center ORA, Baltimore, Maryland, United States
... and 23 other locations.
CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's Lymphoma
Status: Recruiting
Last Changed: Jan 23, 2020
First Received: Jan 23, 2020
Disease(s): Non Hodgkin Lymphoma
Intervention(s): CD19 CAR-T cells infusion
Locations: First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Dietary Milled Seed Mix in Patients With Non-Hodgkin Lymphoma
Status: Recruiting
Last Changed: Mar 20, 2020
First Received: Aug 24, 2017
Disease(s): Non-hodgkin Lymphoma
Intervention(s): Milled seed mix
Locations: Center of Research Excellence in Nutrition and Metabolism, Institute for Medical Research, University of Belgrade, Belgrade, Serbia
Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19
Status: Recruiting
Last Changed: Sep 06, 2019
First Received: Apr 13, 2018
Disease(s): Non-hodgkin Lymphoma,B Cell
Intervention(s): TriCAR-T-CD19
Locations: Hunan Provincial People's Hospital, Changsha, Hunan, China
Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma
Status: Not yet recruiting
Last Changed: Jun 04, 2019
First Received: Jun 04, 2019
Disease(s): Non-hodgkin's Lymphoma
Intervention(s): Chiauranib, Chidamide
Locations: Beijing Cancer Hospital, Beijing, Beijing, China